Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects

被引:54
作者
Sekino, K
Kubota, T
Okada, Y
Yamada, Y
Yamamoto, K
Horiuchi, R
Kimura, K
Iga, T
机构
[1] Tokyo Univ Hosp, Fac Med, Dept Pharm, Bunkyo Ku, Tokyo 1138655, Japan
[2] Gunma Univ, Sch Med, Dept Clin Pharmacol, Div Nephrol & Hypertens, Gunma, Japan
[3] St Marianna Univ, Sch Med, Dept Internal Med, Kanagawa, Japan
关键词
CYP2C9; phenotyping; losartan; pharmacodynamics;
D O I
10.1007/s00228-003-0664-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Losartan is metabolized to the active carboxylic acid metabolite EXP3174 by CYP2C9. In this study, we determined the effects of the single CYP2C9*3 variant on the pharmacokinetics and pharmacodynamics of losartan. Methods: Seven healthy Japanese subjects (CYP2C9*1/*1, n = 4 and CYP2C9*1/*3, n = 3) were phenotyped with a single dose of losartan (25 mg). Blood and urine samples were collected and assayed for losartan and EXP3174. Blood pressure and pulse rate were also measured using a sphygmomanometer. Results: The maximum plasma concentration of EXP3174 was significantly (P < 0.05) lower in the CYP2C9*1/*3 (n = 3) group than in the CYP2C9*1/*1 (n = 4) group. Diastolic blood pressure in the CYP2C9*1/ *1 group, but not that in the CYP2C9*1/*3 group except for at 6 It and 8 h, was reduced from 1.5 h to 12 h compared with the baseline level. Systolic blood pressure in the CYP2C9*1/*1 group, but not that in the CYP2C9*1/*3 group, was reduced from 1 h to 12 h compared with the baseline level. The metabolic ratio (MR) of EXP3174 concentration to the losartan concentration in plasma at 6 h post-dosing and the 4-h to 8-h urinary EXP3174/losartan MR were significantly lower in the CYP2C9*1/*3 group than in the CYP2C9*1/*1 group. The plasma 6-h MR and the 4-h to 8-h urinary MR were significantly (P < 0.05) correlated with the plasma AUC ratio (AUC(EXP3174)/AUC(losartan)), with Spearman rank correlation coefficients of 0.75 and 0.89, respectively. Conclusion: The single CYP2C9*3 variant reduces the metabolism of losartan and its hypotensive effect. Plasma MR, as well as urine MR, may be useful for phenotyping assays of CYP2C9 activity.
引用
收藏
页码:589 / 592
页数:4
相关论文
共 25 条
  • [1] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
    Aithal, GP
    Day, CP
    Kesteven, PJL
    Daly, AK
    [J]. LANCET, 1999, 353 (9154) : 717 - 719
  • [2] Phenytoin metabolic ratio:: a putative marker of CYP2C9 activity in vivo
    Caraco, Y
    Muszkat, M
    Wood, AJJ
    [J]. PHARMACOGENETICS, 2001, 11 (07): : 587 - 596
  • [3] The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase
    Crespi, CL
    Miller, VP
    [J]. PHARMACOGENETICS, 1997, 7 (03): : 203 - 210
  • [4] Clinical relevance of genetic polymorphisms in the human CYP2C subfamily
    Goldstein, JA
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (04) : 349 - 355
  • [5] Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174
    Kaukonen, KM
    Olkkola, KT
    Neuvonen, PJ
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 53 (06) : 445 - 449
  • [6] Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers
    Kazierad, DJ
    Martin, DE
    Blum, RA
    Tenero, DM
    Ilson, B
    Boike, SC
    Etheredge, R
    Jorkasky, DK
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (04) : 417 - 425
  • [7] Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers
    Kirchheiner, J
    Bauer, S
    Meineke, I
    Rohde, W
    Prang, V
    Meisel, C
    Roots, I
    Brockmöller, J
    [J]. PHARMACOGENETICS, 2002, 12 (02): : 101 - 109
  • [8] Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans
    Lo, MW
    Goldberg, MR
    McCrea, JB
    Lu, H
    Furtek, CI
    Bjornsson, TD
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (06) : 641 - 649
  • [9] Cytochrome P4502C9: an enzyme of major importance in human drug metabolism
    Miners, JO
    Birkett, DJ
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 45 (06) : 525 - 538
  • [10] DRUG CONCENTRATION RESPONSE RELATIONSHIPS IN NORMAL VOLUNTEERS AFTER ORAL-ADMINISTRATION OF LOSARTAN, AN ANGIOTENSIN-II RECEPTOR ANTAGONIST
    MUNAFO, A
    CHRISTEN, Y
    NUSSBERGER, J
    SHUM, LY
    BORLAND, RM
    LEE, RJ
    WAEBER, B
    BIOLLAZ, J
    BRUNNER, HR
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (05) : 513 - 521